{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wang Y"],"funding":["Beijing Xisike Clinical Oncology Research Foundation"],"pagination":["87"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12872706"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["105(3)"],"pubmed_abstract":["<h4>Background</h4>Adding daratumumab to initial therapy in randomized controlled trials (RCTs) for newly diagnosed multiple myeloma (MM) enhances deep remission and prolongs progression-free survival (PFS). Given the differences between trial-eligible and real-world patients, and healthcare access variability in developing countries, real-world data are essential to complement RCT evidence.<h4>Methods</h4>We analyzed 761 newly diagnosed MM patients treated with (n = 177) or without (n = 584) daratumumab as first-line therapy from 2017 to 2023 across southern China. Propensity score matching (PSM) generated cohorts of 158 and 278 patients, respectively, matched for stage, cytogenetic abnormalities, and regimen type. Responses were evaluated per International Myeloma Working Group criteria,"],"journal":["Annals of hematology"],"pubmed_title":["Daratumumab-based first-line therapy benefit multiple myeloma patients in a real-world setting: a multi-center retrospective propensity score-match study."],"pmcid":["PMC12872706"],"funding_grant_id":["Y-Young2022- -0281"],"pubmed_authors":["Fu X","Liang Y","Zhang H","Dong M","Du X","Wei Y","Wang W","Chen X","Wang X","Wang Y","Su Y","Zhou H","Peter Gale R","Liang Q","Zhou J","Xia Z","Sun Z","Peng H","Luo J","Huang Z","Hu G","Luo L","Tian Y","Tao S","Lan M","Feng R","Zhong L"],"additional_accession":[]},"is_claimable":false,"name":"Daratumumab-based first-line therapy benefit multiple myeloma patients in a real-world setting: a multi-center retrospective propensity score-match study.","description":"<h4>Background</h4>Adding daratumumab to initial therapy in randomized controlled trials (RCTs) for newly diagnosed multiple myeloma (MM) enhances deep remission and prolongs progression-free survival (PFS). Given the differences between trial-eligible and real-world patients, and healthcare access variability in developing countries, real-world data are essential to complement RCT evidence.<h4>Methods</h4>We analyzed 761 newly diagnosed MM patients treated with (n = 177) or without (n = 584) daratumumab as first-line therapy from 2017 to 2023 across southern China. Propensity score matching (PSM) generated cohorts of 158 and 278 patients, respectively, matched for stage, cytogenetic abnormalities, and regimen type. Responses were evaluated per International Myeloma Working Group criteria,","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-16T20:25:12.181Z","creation":"2026-07-10T03:10:01.553Z"},"accession":"S-EPMC12872706","cross_references":{"pubmed":["41639272"],"doi":["10.1007/s00277-026-06808-5"]}}